Mirati Therapeutics, Inc.
MRTXNASDAQHealthcare
$58.70
$-0.10(-0.17%)
Market Cap$4.1B
P/E Ratio—
52W High$64.41
52W Low$27.3
Mirati Therapeutics, Inc. (MRTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MRTX · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2024Report Date: Feb 27, 2024EPS Actual
-$3.51
Est. -$2.66 · -31.9%
Revenue
—
Est. $0.02B
Fiscal Period
Q1 FY2024
FY ends December
Report Date
Feb 27, 2024
After Market Close
▼ Miss EPS
MRTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $1.10B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$1.10B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q1 FY2024 | Feb 27, 2024 | -$2.66 | -$3.51 | -31.9% | — | $0.02B | — |
| ▲ Q4 FY2023 | Nov 6, 2023 | -$2.92 | -$2.49 | +14.7% | $0.02B | $0.03B | -35.5% |
| ▲ Q3 FY2023 | Aug 8, 2023 | -$3.23 | -$3.04 | +5.9% | $0.01B | $0.01B | +1.3% |
| ▲ Q2 FY2023 | May 9, 2023 | -$3.47 | -$3.18 | +8.4% | $0.01B | $0.00B | +49.9% |
| ▲ Q1 FY2023 | Feb 28, 2023 | -$3.74 | -$3.51 | +6.2% | $0.00B | $0.00B | -58.9% |
| ▲ Q4 FY2022 | Nov 8, 2022 | -$3.46 | -$3.09 | +10.7% | $0.01B | — | — |
| ▲ Q3 FY2022 | Aug 3, 2022 | -$3.53 | -$3.18 | +9.9% | $0.01B | — | — |
| — Q2 FY2022 | May 4, 2022 | -$3.37 | -$3.40 | -0.9% | $0.00B | $0.00B | -2.5% |
Q1 FY2024
Feb 27, 2024Miss
EPS Actual
-$3.51
EPS Est.
-$2.66
EPS Surpr.
-31.9%
Revenue
—
Q4 FY2023
Nov 6, 2023Beat
EPS Actual
-$2.49
EPS Est.
-$2.92
EPS Surpr.
+14.7%
Revenue
$0.02B
Q3 FY2023
Aug 8, 2023Beat
EPS Actual
-$3.04
EPS Est.
-$3.23
EPS Surpr.
+5.9%
Revenue
$0.01B
Q2 FY2023
May 9, 2023Beat
EPS Actual
-$3.18
EPS Est.
-$3.47
EPS Surpr.
+8.4%
Revenue
$0.01B
Q1 FY2023
Feb 28, 2023Beat
EPS Actual
-$3.51
EPS Est.
-$3.74
EPS Surpr.
+6.2%
Revenue
$0.00B
Q4 FY2022
Nov 8, 2022Beat
EPS Actual
-$3.09
EPS Est.
-$3.46
EPS Surpr.
+10.7%
Revenue
$0.01B
Q3 FY2022
Aug 3, 2022Beat
EPS Actual
-$3.18
EPS Est.
-$3.53
EPS Surpr.
+9.9%
Revenue
$0.01B
Q2 FY2022
May 4, 2022
EPS Actual
-$3.40
EPS Est.
-$3.37
EPS Surpr.
-0.9%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $2.04 | $1.54 | $0.76 | 0 |
| Q2 FY2024 | $1.78 | $1.34 | $0.66 | 0 |
| Q1 FY2024 | $2.09 | $1.58 | $0.78 | 2 |
| Q4 FY2023 | $-3.56 | $-2.69 | $-1.33 | 12 |
| Q3 FY2023 | $-3.34 | $-2.83 | $-1.86 | 17 |
| Q2 FY2023 | $-4.27 | $-3.23 | $-1.60 | 7 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.1B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.1B | 1 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 10 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 14 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 13 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2024 | Feb 27, 2024 | -31.9% | $58.70 | — | — |
| ▲ Q4 FY2023 | Nov 6, 2023 | +14.7% | $56.02 | $56.27 | +0.45% |
| ▲ Q3 FY2023 | Aug 8, 2023 | +5.9% | $28.06 | $27.80 | -0.93% |
| ▲ Q2 FY2023 | May 9, 2023 | +8.4% | $46.37 | $47.31 | +2.03% |
| ▲ Q1 FY2023 | Feb 28, 2023 | +6.2% | $46.24 | $45.84 | -0.87% |
| ▲ Q4 FY2022 | Nov 8, 2022 | +10.7% | $59.92 | $59.44 | -0.80% |
| ▲ Q3 FY2022 | Aug 3, 2022 | +9.9% | $70.05 | $71.78 | +2.47% |
| ▲ Q2 FY2022 | May 4, 2022 | -0.9% | $64.26 | $64.02 | -0.37% |
Q1 FY2024—
Report Date
Feb 27, 2024
EPS Beat/Miss
-31.9%
Price Before
$58.70
Price After
—
Q4 FY2023+0.45%
Report Date
Nov 6, 2023
EPS Beat/Miss
+14.7%
Price Before
$56.02
Price After
$56.27
Q3 FY2023-0.93%
Report Date
Aug 8, 2023
EPS Beat/Miss
+5.9%
Price Before
$28.06
Price After
$27.80
Q2 FY2023+2.03%
Report Date
May 9, 2023
EPS Beat/Miss
+8.4%
Price Before
$46.37
Price After
$47.31
Q1 FY2023-0.87%
Report Date
Feb 28, 2023
EPS Beat/Miss
+6.2%
Price Before
$46.24
Price After
$45.84
Q4 FY2022-0.80%
Report Date
Nov 8, 2022
EPS Beat/Miss
+10.7%
Price Before
$59.92
Price After
$59.44
Q3 FY2022+2.47%
Report Date
Aug 3, 2022
EPS Beat/Miss
+9.9%
Price Before
$70.05
Price After
$71.78
Q2 FY2022-0.37%
Report Date
May 4, 2022
EPS Beat/Miss
-0.9%
Price Before
$64.26
Price After
$64.02
Avg Beat Reaction+0.28%
Beat Rate7 / 8 quarters
Largest Move+2.47% (Q3 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MRTX ends December
Mirati Therapeutics, Inc. (MRTX) most recently reported earnings on February 27, 2024 for Q1 FY2024, posting EPS of $-3.51 — missing the analyst consensus of $-2.66 by -31.9%. The next MRTX earnings date is expected around September 1, 2026.
Each quarter, investors track MRTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MRTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MRTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MRTX earnings · 5 questionsMirati Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. MRTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MRTX historically reports after market close (AMC).
MRTX earnings datewhen is MRTX earningsMRTX next earnings datewhen does MRTX report earningsMRTX earnings calendar
▸ Source: FMP · Mirati Therapeutics, Inc. SEC filings · US GAAP · Mirati Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026